The “Calcium Paradox” Due To Ca2+/Camp Interaction: New Insights for the Neuroscience Field
Article Sidebar
Main Article Content
Abstract
In the cardiovascular field, tachycardia and increment of catecholamine plasma levels (sympathetic hyperactivity) have been reported by hypertensive patients that use L-type Ca2+ channel blockers (CCBs) since 70´s. Our discovery of the involvement of interaction between the intracellular signalling pathways mediated by Ca2+ and cAMP (Ca2+/cAMP interaction) revealed that this phenomenon (sympathetic hyperactivity) was resulting of increase of transmitter release from sympathetic neurons stimulated by CCBs due to its interference on the Ca2+/cAMP interaction. In the neuroscience field, this discovery has produced new paths for the understanding of the cellular and molecular mechanisms involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer´s and Parkinson’s diseases. In this way, novel journeys for the development of new pharmacological strategies more effective for the treatment of neurodegenerative diseases may be initiated.
Article Details
Copyright (c) 2017 Bergantin LB, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Chern YJ, Kim KT, Slakey LL, Westhead EW. Adenosine receptors activate adenylate cyclase and enhance secretion from bovine adrenal chromaffin cells in the presence of forskolin. J Neurochem. 1988; 50: 1484-1493. Ref.: https://goo.gl/D3U5F0
Douglas WW, Rubin RP. The role of calcium in the secretory response of the adrenal medulla to acetylcholine. J Physiol. 1961; 159: 40-57. Ref.: https://goo.gl/Lwekpm
Baker PF, Knight DE. Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. Nature. 1978; 276: 620-622. Ref.: https://goo.gl/bvf8DR
Neher E, Zucker RS. Multiple calcium-dependent processes related to secretion in bovine chromaffin cells. Neuron. 1993; 10: 21-30. Ref.: https://goo.gl/3fvzjy
Caricati-Neto A, García AG, Bergantin LB. Pharmacological implications of the Ca2+/cAMP signalling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect. 2015; 3: e00181. Ref.: https://goo.gl/UiQrGs
Bergantin LB, Souza CF, Ferreira RM, Smaili SS, Jurkiewicz NH, et al. Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium. 2013; 54: 202-212. Ref.: https://goo.gl/HHou6F
Bergantin LB, Jurkiewicz A, García AG, Caricati-Neto A. A Calcium Paradox in the Context of Neurotransmission. Journal of Pharmacy and Pharmacology. 2015; 3: 253-261. Ref.: https://goo.gl/ltkVhv
Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca2+/cAMP intracellular signalling interaction. Eur J Pharmacol. 2016; 788: 255-260. Ref.: https://goo.gl/u21xBi
Grossman E, Messerli FH. Effect of calcium antagonists on sympathetic activity. Eur Heart J. 1998; 19: F27-F31. Ref.: https://goo.gl/BQkkG1
Kreye VA, Luth JB. Proceedings: verapamil-induced phasic contractions of the isolated rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1975; 287: R43. Ref.: https://goo.gl/Z07NA4
French AM, Scott NC. A comparison of the effects of nifedipine and verapamil on rat vas deferens. Br J Pharmacol. 1981; 73: 321-323. Ref.: https://goo.gl/d8wrcd
Moritoki H, Iwamoto T, Kanaya J, Maeshiba Y, Ishida Y, et al. Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur J Pharmacol. 1987; 140: 75-83. Ref.: https://goo.gl/OKoviM
Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1995; 1: 244-248. Ref.: https://goo.gl/MiganR
Xiao L, O'Callaghan JP, O'Donnell JM. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther. 2011; 338: 641-647. Ref.: https://goo.gl/14xO4A
Bergantin LB, Caricati-Neto A. Novel Insights for Therapy of Parkinson’s disease: Pharmacological Modulation of the Ca2+/cAMP Signalling Interaction. Austin Neurol & Neurosci. 2016; 1: 1009. Ref.: https://goo.gl/ujivdj
Bergantin LB, Caricati-Neto A. Recent advances in pharmacotherapy of neurological and psychiatric disorders promoted by discovery of the role of Ca2+/cAMP signaling interaction in the neurotransmission and neuroprotection. Adv Pharmac J. 2016; 1: 66.
Halls ML, Cooper DM. Adenylyl cyclase signalling complexes - Pharmacological challenges and opportunities. Pharmacol Ther. 2017; 7258: 30011-30016. Ref.: https://goo.gl/VDeVKV
Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature. 1995; 374: 421-424. Ref.: https://goo.gl/OVc1JP
Bereczki E, Francis PT, Howlett D, Pereira JB, Höglund K, et al. Synaptic proteins predict cognitive decline in Alzheimer`s disease and Lewy body dementia. Alzheimers Dement. 2016; 12: 1149-1158. Ref.: https://goo.gl/pch8Cq
Clare R, King VG, Wirenfeldt M, Vinters HV. Synapse loss in dementias. J Neurosci Res. 2010; 88: 2083-2090. Ref.: https://goo.gl/5sJRu7